REPORTS

Let’s Pullulate and Expand Your Business

Oncology Biosimilar Market - Global Professional Analysis and Forecast to 2026

Oct 15, 2019  |  146 PAGES  |  REPORT CODE: CMM211815
  • REPORT SUMMARY
  • TABLE OF CONTENTS
  • INDUSTRY COVERAGE

The worldwide Oncology Biosimilar market was valued at XX.0 Million US$ in 2018 and is projected to reach XX.0 Million US$ by 2026, at a CAGR (Compound Annual Growth Rate) of 7.3% during the forecast period.

This report presents the market size and development trends by detailing the Oncology Biosimilar market revenue, market share and growth rate from 2015-2026, and it gives a thorough analysis by various product types, applications, regions, and main participants. The market conditions (2015-2019), corporate competition pattern, corporate SWOT analysis are elaborated, and other qualitative analyses like market dynamics, market penetration, market business environment analyses, the regional regulatory scenario in the Oncology Biosimilar market will be shown in this report. In short, this report will comprehensively reveal the characteristics of Oncology Biosimilar industry and will help you to build a panoramic view of the industrial development.

Oncology Biosimilar Market, By Type:

  • Protein

  • Hormones

  • Uucleic Acids

Oncology Biosimilar Market, By Application:

  • End-Users 1

  • End-Users 2

  • End-Users 3

Some of the leading players are as follows:

  • Boehringer Ingelheim

  • Amgen

  • Sandoz

  • Allergan

  • Dr. Reddy's Laboratories

  • Mylan

  • Biocon

  • AbbVie

  • Hospira

  • Celltrion

  • F. Hoffmann-La Roche

  • AstraZeneca

  • Biogen

  • BioXpress Therapeutics

  • Baxter

Geographically, Major regions are analyzed in details are as follows:

  • North America

  • Europe

  • Asia Pacific

  • Latin America

  • Middle East & Africa

Table of Contents

1 Methodology and Scope

  • 1.1 Market Segmentation & Scope

    • 1.1.1 Technology Type

    • 1.1.2 Product

    • 1.1.3 Application

    • 1.1.4 Regional scope

    • 1.1.5 Estimates and forecast timeline

  • 1.2 Research Methodology

  • 1.3 Information Procurement

    • 1.3.1 Purchased database

    • 1.3.2 Internal database

    • 1.3.3 Secondary sources

    • 1.3.4 Primary research

    • 1.3.5 Details of primary research

  • 1.4 Information or Data Analysis

    • 1.4.1 Data analysis models

  • 1.5 Market Formulation & Validation

  • 1.6 Model Details

    • 1.6.1 Commodity flow analysis

    • 1.6.2 Volume price analysis

  • 1.7 List of Secondary Sources

  • 1.8 List of Abbreviations

2 Executive Summary

  • 2.1 Market Outlook

  • 2.2 Segment Outlook

3 Market Variables, Trends, & Scope

  • 3.1 Market Lineage Outlook

  • 3.1.1 Parent market outlook

    • 3.1.2 Ancillary market outlook

  • 3.2 Market Segmentation

    • 3.2.1 Analysis

  • 3.3 Market Dynamics

    • 3.3.1 Market driver analysis

    • 3.3.2 Market restraint analysis

    • 3.3.3 Industry opportunities

  • 3.4 Penetration & Growth Prospect Mapping

    • 3.4.1 Penetration & growth prospect mapping analysis

  • 3.5 Business Environment Analysis Tools

    • 3.5.1 Porter's five forces analysis

    • 3.5.2 PESTLE analysis

    • 3.5.3 Major deals & strategic alliances analysis

4 Oncology Biosimilar Market: Technology Type Analysis

  • 4.1 Oncology Biosimilar Technology Type Market Share Analysis, 2018 & 2026

  • 4.2 Oncology Biosimilar Technology Type Market: Segment Dashboard

  • 4.3 Market Size & Forecasts and Trend Analyses, 2015 to 2026 for the Technology Type Segment

    • 4.3.1 Protein

    • 4.3.2 Hormones

    • 4.3.3 Uucleic Acids

5 Oncology Biosimilar Market: Product Analysis

  • 5.1 Oncology Biosimilar Product Market Share Analysis, 2018 & 2026

  • 5.2 Oncology Biosimilar Product Market: Segment Dashboard

  • 5.3 Market Size & Forecasts and Trend Analyses, 2015 to 2026 for the Product Segment

6 Oncology Biosimilar Market: Application Analysis

  • 6.1 Oncology Biosimilar Application Market Share Analysis, 2018 & 2026

  • 6.2 Oncology Biosimilar Application Market: Segment Dashboard

  • 6.3 Market Size & Forecasts and Trend Analyses, 2015 to 2026 for the Application Segment

    • 6.3.1 End-User 1

    • 6.3.2 End-User 1

    • 6.3.3 End-User 3

7 Oncology Biosimilar Market: Regional Analysis

  • 7.1 Oncology Biosimilar Regional Market Share Analysis, 2018 & 2026

  • 7.2 Oncology Biosimilar Regional Market: Segment Dashboard

  • 7.3 Regional Market Snapshot (Market Size, CAGR, Top Countries)

  • 7.4 List of Players at Regional Level

    • 7.4.1 North America

    • 7.4.2 Europe

    • 7.4.3 Asia Pacific

  • 7.5 SWOT Analysis, by Factor (Political & Legal, Economic and Technological)

    • 7.5.1 North America

    • 7.5.2 Europe

    • 7.5.3 Asia Pacific

    • 7.5.4 Latin America

    • 7.5.5 MEA

  • 7.6 Market Size & Forecasts, and Trend Analysis, 2015 to 2026

    • 7.6.1 North America

    • 7.6.2 Europe

    • 7.6.3 Asia Pacific

    • 7.6.4 Latin America

    • 7.6.5 Middle East & Africa

8 Competitive Analysis

  • 8.1 Recent Developments & Impact Analysis, by Key Market Participants

  • 8.2 Strategic Framework/Competition Categorization (Key innovators, Market leaders, Emerging players)

  • 8.3 Vendor Landscape

    • 8.3.1 Company market position analysis (Geographic presence, service portfolio, strategic initiatives)

9 Company Profiles

  • 9.1 Boehringer Ingelheim

    • 9.1.1 Boehringer Ingelheim Company overview

    • 9.1.2 Financial performance

    • 9.1.3 Product benchmarking

    • 9.1.4 Strategic initiatives

    • 9.1.5 SWOT analysis

  • 9.2 Amgen

    • 9.2.1 Amgen Company overview

    • 9.2.2 Financial performance

    • 9.2.3 Product benchmarking

    • 9.2.4 Strategic initiatives

    • 9.2.5 SWOT analysis

  • 9.3 Sandoz

    • 9.3.1 Sandoz Company overview

    • 9.3.2 Financial performance

    • 9.3.3 Product benchmarking

    • 9.3.4 Strategic initiatives

    • 9.3.5 SWOT analysis

  • 9.4 Allergan

    • 9.4.1 Allergan Company overview

    • 9.4.2 Financial performance

    • 9.4.3 Product benchmarking

    • 9.4.4 Strategic initiatives

    • 9.4.5 SWOT analysis

  • 9.5 Dr. Reddy's Laboratories

    • 9.5.1 Dr. Reddy's Laboratories Company overview

    • 9.5.2 Financial performance

    • 9.5.3 Product benchmarking

    • 9.5.4 Strategic initiatives

    • 9.5.5 SWOT analysis

  • 9.6 Mylan

    • 9.6.1 Mylan Company overview

    • 9.6.2 Financial performance

    • 9.6.3 Product benchmarking

    • 9.6.4 Strategic initiatives

    • 9.6.5 SWOT analysis

  • 9.7 Biocon

    • 9.7.1 Biocon Company overview

    • 9.7.2 Financial performance

    • 9.7.3 Product benchmarking

    • 9.7.4 Strategic initiatives

    • 9.7.5 SWOT analysis

  • 9.8 AbbVie

    • 9.8.1 AbbVie Company overview

    • 9.8.2 Financial performance

    • 9.8.3 Product benchmarking

    • 9.8.4 Strategic initiatives

    • 9.8.5 SWOT analysis

  • 9.9 Hospira

    • 9.9.1 Hospira Company overview

    • 9.9.2 Financial performance

    • 9.9.3 Product benchmarking

    • 9.9.4 Strategic initiatives

    • 9.9.5 SWOT analysis

  • 9.10 Celltrion

    • 9.10.1 Celltrion Company overview

    • 9.10.2 Financial performance

    • 9.10.3 Product benchmarking

    • 9.10.4 Strategic initiatives

    • 9.10.5 SWOT analysis

  • 9.11 F. Hoffmann-La Roche

    • 9.11.1 F. Hoffmann-La Roche Company overview

    • 9.11.2 Financial performance

    • 9.11.3 Product benchmarking

    • 9.11.4 Strategic initiatives

    • 9.11.5 SWOT analysis

  • 9.12 AstraZeneca

    • 9.12.1 AstraZeneca Company overview

    • 9.12.2 Financial performance

    • 9.12.3 Product benchmarking

    • 9.12.4 Strategic initiatives

    • 9.12.5 SWOT analysis

  • 9.13 Biogen

    • 9.13.1 Biogen Company overview

    • 9.13.2 Financial performance

    • 9.13.3 Product benchmarking

    • 9.13.4 Strategic initiatives

    • 9.13.5 SWOT analysis

  • 9.14 BioXpress Therapeutics

    • 9.14.1 BioXpress Therapeutics Company overview

    • 9.14.2 Financial performance

    • 9.14.3 Product benchmarking

    • 9.14.4 Strategic initiatives

    • 9.14.5 SWOT analysis

  • 9.15 Baxter

    • 9.15.1 Baxter Company overview

    • 9.15.2 Financial performance

    • 9.15.3 Product benchmarking

    • 9.15.4 Strategic initiatives

    • 9.15.5 SWOT analysis

 

The List of Tables and Figures (Totals 93 Figures and 120 Tables)

  • Figure Protein Oncology Biosimilar market, 2015 - 2026 (USD Million)

  • Figure Hormones Oncology Biosimilar market, 2015 - 2026 (USD Million)

  • Figure Uucleic Acids Oncology Biosimilar market, 2015 - 2026 (USD Million)

  • Figure End-Users 1 market, 2015 - 2026 (USD Million)

  • Figure End-Users 2 market, 2015 - 2026 (USD Million)

  • Figure End-Users 3 market, 2015 - 2026 (USD Million)

  • Table List of players in North America

  • Table List of players in Europe

  • Table List of players in Asia Pacific

  • Table SWOT analysis

  • Table North America Oncology Biosimilar market, by country, 2015 - 2026 (USD Million)

  • Table North America Oncology Biosimilar market, by type, 2015 - 2026 (USD Million)

  • Table North America Oncology Biosimilar market, by product, 2015 - 2026 (USD Million)

  • Table North America Oncology Biosimilar market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table U.S. Oncology Biosimilar market, by type, 2015 - 2026 (USD Million)

  • Table U.S. Oncology Biosimilar market, by product, 2015 - 2026 (USD Million)

  • Table U.S. Oncology Biosimilar market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table Canada Oncology Biosimilar market, by type, 2015 - 2026 (USD Million)

  • Table Canada Oncology Biosimilar market, by product, 2015 - 2026 (USD Million)

  • Table Canada Oncology Biosimilar market, by application, 2015 - 2026 (USD Million)

  • Table Europe Oncology Biosimilar market, by country, 2015 - 2026 (USD Million)

  • Table Europe Oncology Biosimilar market, by type, 2015 - 2026 (USD Million)

  • Table Europe Oncology Biosimilar market, by product, 2015 - 2026 (USD Million)

  • Table Europe Oncology Biosimilar market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table U.K. Oncology Biosimilar market, by type, 2015 - 2026 (USD Million)

  • Table U.K. Oncology Biosimilar market, by product, 2015 - 2026 (USD Million)

  • Table U.K. Oncology Biosimilar market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table Germany Oncology Biosimilar market, by type, 2015 - 2026 (USD Million)

  • Table Germany Oncology Biosimilar market, by product, 2015 - 2026 (USD Million)

  • Table Germany Oncology Biosimilar market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table France Oncology Biosimilar market, by type, 2015 - 2026 (USD Million)

  • Table France Oncology Biosimilar market, by product, 2015 - 2026 (USD Million)

  • Table France Oncology Biosimilar market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table Italy Oncology Biosimilar market, by type, 2015 - 2026 (USD Million)

  • Table Italy Oncology Biosimilar market, by product, 2015 - 2026 (USD Million)

  • Table Italy Oncology Biosimilar market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table Spain Oncology Biosimilar market, by type, 2015 - 2026 (USD Million)

  • Table Spain Oncology Biosimilar market, by product, 2015 - 2026 (USD Million)

  • Table Spain Oncology Biosimilar market, by application, 2015 - 2026 (USD Million)

  • Table Asia Pacific Oncology Biosimilar market, by country, 2015 - 2026 (USD Million)

  • Table Asia Pacific Oncology Biosimilar market, by type, 2015 - 2026 (USD Million)

  • Table Asia Pacific Oncology Biosimilar market, by product, 2015 - 2026 (USD Million)

  • Table Asia Pacific Oncology Biosimilar market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table China Oncology Biosimilar market, by type, 2015 - 2026 (USD Million)

  • Table China Oncology Biosimilar market, by product, 2015 - 2026 (USD Million)

  • Table China Oncology Biosimilar market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table Japan Oncology Biosimilar market, by type, 2015 - 2026 (USD Million)

  • Table Japan Oncology Biosimilar market, by product, 2015 - 2026 (USD Million)

  • Table Japan Oncology Biosimilar market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table India Oncology Biosimilar market, by type, 2015 - 2026 (USD Million)

  • Table India Oncology Biosimilar market, by product, 2015 - 2026 (USD Million)

  • Table India Oncology Biosimilar market, by application, 2015 - 2026 (USD Million)

  • Table Latin America Oncology Biosimilar market, by country, 2015 - 2026 (USD Million)

  • Table Latin America Oncology Biosimilar market, by type, 2015 - 2026 (USD Million)

  • Table Latin America Oncology Biosimilar market, by product, 2015 - 2026 (USD Million)

  • Table Latin America Oncology Biosimilar market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table Brazil Oncology Biosimilar market, by type, 2015 - 2026 (USD Million)

  • Table Brazil Oncology Biosimilar market, by product, 2015 - 2026 (USD Million)

  • Table Brazil Oncology Biosimilar market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table Mexico Oncology Biosimilar market, by type, 2015 - 2026 (USD Million)

  • Table Mexico Oncology Biosimilar market, by product, 2015 - 2026 (USD Million)

  • Table Mexico Oncology Biosimilar market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table Argentina Oncology Biosimilar market, by type, 2015 - 2026 (USD Million)

  • Table Argentina Oncology Biosimilar market, by product, 2015 - 2026 (USD Million)

  • Table Argentina Oncology Biosimilar market, by application, 2015 - 2026 (USD Million)

  • Table MEA Oncology Biosimilar market, by country, 2015 - 2026 (USD Million)

  • Table MEA Oncology Biosimilar market, by type, 2015 - 2026 (USD Million)

  • Table MEA Oncology Biosimilar market, by product, 2015 - 2026 (USD Million)

  • Table MEA Oncology Biosimilar market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table South Africa Oncology Biosimilar market, by type, 2015 - 2026 (USD Million)

  • Table South Africa Oncology Biosimilar market, by product, 2015 - 2026 (USD Million)

  • Table South Africa Oncology Biosimilar market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table Nigeria Oncology Biosimilar market, by type, 2015 - 2026 (USD Million)

  • Table Nigeria Oncology Biosimilar market, by product, 2015 - 2026 (USD Million)

  • Table Nigeria Oncology Biosimilar market, by application, 2015 - 2026 (USD Million)

  • Table Recent Developments & Impact Analysis, by Key Market Participants

  • Table Recent Developments & Impact Analysis, by Key Market Participants

  • Table Company market position analysis

  • Table Company Profiles

  • Table Boehringer Ingelheim Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Amgen Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Sandoz Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Allergan Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Dr. Reddy's Laboratories Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Mylan Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Biocon Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table AbbVie Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Hospira Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Celltrion Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table F. Hoffmann-La Roche Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table AstraZeneca Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Biogen Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table BioXpress Therapeutics Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Baxter Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

Report Purchase

reports
$4840
$9680
BUY NOWClick MeBUY NOW
top